Drug
Guselkumab clinical trials
Also written CNTO1959 and Tremfya.
- studies test it
- 80
- open now
- 19
- in phase 3
- 31
- first study started
- 2011
Keep track of what changes. Save the guselkumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
80 studies that test it; most in 2021 (10)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 10 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 13
- Phase 2
- 19
- Phase 3
- 31
- Phase 4
- 15
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 59 · Other 21
Janssen Research & Development, LLC (39) · Janssen Pharmaceutical K.K. (8) · Janssen-Cilag Ltd. (4) · University of California, San Francisco (3) · Oregon Health and Science University (2) · University of California, San Diego (2) · NYU Langone Health (2) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2)
Often tested with
Tested in the same studies.
Ustekinumab (8) · Ixekizumab (6) · Adalimumab (5) · Secukinumab (5) · Risankizumab (5) · Methotrexate (4) · Golimumab (3) · Bimekizumab (3)
Studies
Open first, then newest update. How each study uses guselkumab is read from its arms, and is right about nine times in ten.
Testing it · 80
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingPhase 4Janssen Research & Development, LLCNCT07654751Written as Guselkumab
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Janssen Research & Development, LLCNCT05923073Written as Guselkumab
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingPhase 3Janssen Research & Development, LLCNCT06663332Written as Guselkumab
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)RecruitingPhase 4Xian-Janssen Pharmaceutical Ltd.NCT07310095Written as Guselkumab (GUS)
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Janssen Research & Development, LLCNCT07499232Written as Guselkumab
- A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)RecruitingPhase 4Johnson & Johnson Private LimitedNCT07141004Written as Guselkumab
- A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the ColonNot yet recruitingPhase 1Surmount Services, Inc.NCT07788807Written as Guselkumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Guselkumab
- Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter StudyRecruitingPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT07616687Written as Guselkumab
- Efficacy of Guselkumab in Treating Hailey Hailey DiseaseRecruitingPhase 2Yale UniversityNCT06651489Written as Guselkumab
- Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab TherapyRecruitingNot applicableUniversity of California, San DiegoNCT06586281Written as Guselkumab
- Immune Spatial Features of Guselkumab Cutaneous ResponseRecruitingPhase 4University of California, San FranciscoNCT05858632Written as Guselkumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Guselkumab
- A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque PsoriasisRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07532486Written as Guselkumab
- Multi-Center PAMPA StudyRecruitingPhase 4NYU Langone HealthNCT05004727Written as Guselkumab
- Proactive TDM Versus Standard Use of Biologics in PsoriasisRecruitingPhase 4University Hospital, GhentNCT06398106Written as Proactive TDM-based dosing of guselkumab
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder PatientsRecruitingPhase 3University of PennsylvaniaNCT05669833Written as Guselkumab
- Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.RecruitingPhase 4Fondazione Policlinico Universitario Campus Bio-MedicoNCT06974474Written as Guselkumab
- Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05503875Written as adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
- A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCompletedPhase 3Janssen Pharmaceutical K.K.NCT04397263Written as Guselkumab
See all 80 studies that test guselkumab →
Given in every arm · 5 — guselkumab is usual care beside what is tested
- GUselkumAb inteRvention and DIet evaluAtioN for PouchitisRecruitingPhase 4Universitaire Ziekenhuizen KU LeuvenNCT06916390Written as Guselkumab
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsActive, not recruitingPhase 3Janssen Research & Development, LLCNCT03451851Written as Guselkumab
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic ArthritisCompletedPhase 2Janssen Research & Development, LLCNCT05071664Written as Guselkumab
- A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisCompletedPhase 3Janssen Research & Development, LLCNCT02207231Written as Guselkumab 100 mg
- A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and RetreatmentCompletedPhase 3Janssen Research & Development, LLCNCT02207244Written as Guselkumab 100 mg
As the comparator · 4 — what is tested is compared with guselkumab
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Janssen Research & Development, LLCNCT07577843Written as Guselkumab
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Janssen Research & Development, LLCNCT07577856Written as Guselkumab
- A Phase 3 Clinical Study of QL2106 InjectionActive, not recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07511647Written as Tremfya®
- Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to UstekinumabTerminatedPhase 4LEO PharmaNCT04533737Written as Guselkumab
Codes
What other systems call guselkumab · ClinicalTrials.gg INT000013
- MeSH (NLM) C000588857guselkumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 089658A12DGUSELKUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1928588Confirmed FDA, Wikidata
- Wikidata Q15708315guselkumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C150390GuselkumabOne source FDA
- DrugBank DB11834One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000588857 | guselkumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 089658A12D | GUSELKUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1928588 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708315 | guselkumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C150390 | Guselkumab | One source FDA |
| DrugBank | DB11834 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.